AKT1 and breast carcinoma: AKT inhibitors are classified into three broad categories: ATP-competitive, allosteric, and covalent allosteric inhibitors, with capivasertib being the first drug to receive FDA approval in combination with the estrogen receptor degrader fulvestrant for breast cancer treatment 103.